Haloperidol LACTATE (Haldol ®)
|The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.|
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]
| [0 to 10 mg] [50 ml] [As directed]
HALDOL INJECTION IS NOT APPROVED FOR INTRAVENOUS ADMINISTRATION.
[See WARNING below]
Stability / Miscellaneous
| EXP: 7 DAYS (RT)
Label: Do not Refrigerate. Protect from light.
Oral to IV conversion (approximate): oral dose x 0.625 = daily IV dose.
DOSAGE AND ADMINISTRATION
To determine the initial dosage, consideration should be given to the patient's age, severity of illness, previous response to other antipsychotic drugs, and any concomitant medication or disease state. Debilitated or geriatric patients, as well as those with a history of adverse reactions to antipsychotic drugs, may require less HALDOL (haloperidol). The optimal response in such patients is usually obtained with more gradual dosage adjustments and at lower dosage levels.
Parenteral medication, administered intramuscularly in doses of 2 to 5 mg, is utilized for prompt control of the acutely agitated schizophrenic patient with moderately severe to very severe symptoms. Depending on the response of the patient, subsequent doses may be given, administered as often as every hour, although 4 to 8 hour intervals may be satisfactory.
Controlled trials to establish the safety and effectiveness of intramuscular administration in children have not been conducted.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Elderly Patients: Patients over 65 years old generally should not receive >2 mg/24 hours. If higher doses are given, (ECG) monitoring is recommended. Usual starting doses are 0.25 - 0.5 mg given no more than twice a day.
Source: [package insert]